When people ask their doctors about lupus causes, their answer can sometimes sound frustratingly vague. While they know that genetics plays a role, as do hormones and the environment, specific triggers have largely remained elusive. A new study from Stanford University now pushes one suspect, Epstein-Barr virus, to the center of the stage. Younis and colleagues used cutting-edge single-cell sequencing to track how this childhood virus can hijack immune cells and push them toward autoimmunity in systemic lupus erythematosus. Senior author William Robinson called the finding “the single most impactful finding to emerge from my lab in my entire career.” The work does not mean Epstein-Barr virus explains every detail of lupus, but it provides the strongest mechanistic link so far between Epstein-Barr virus and lupus. It sharpens how scientists talk about lupus causes and helps explain why a nearly universal virus triggers disease only in some people.
Rethinking Lupus Causes In Light Of A Common Virus
Lupus is a chronic autoimmune disease where the immune system attacks healthy tissues, including skin, joints, kidneys, and brain. For decades, researchers have argued that the causes of lupus cannot be reduced to a single gene or single trigger. The StatPearls lupus chapter notes that “genetic, immunological, endocrine, and environmental factors influence the loss of immunological tolerance against self-antigens.” That quote very much captures the modern view. Genes may set the stage, yet the hormones and exposures help determine who actually gets sick. Environmental research over several decades reveals that ultraviolet light, infections, and certain medications can push susceptible immune systems off balance.
The Lupus Foundation of America now lists infections, especially Epstein-Barr virus, among the leading environmental suspects. While this new Stanford work does not replace that overview, it helps explain how one particular infection could fit inside it. The virus appears to reprogram a very specific set of B cells that already carry lupus risk features. So the study shifts the conversation about lupus causes away from vague “triggers” and toward a defined pathway that links infection, risk genes, and rogue immune cells.
What Epstein-Barr Virus Does Inside The Body
Epstein-Barr virus, also called human herpesvirus 4, is almost impossible to avoid. The U.S. Centers for Disease Control and Prevention notes that “EBV is one of the most common human viruses in the world.” Most people catch it in childhood or adolescence, usually through saliva. The infection can cause mononucleosis or pass with few symptoms, then persists for life inside B cells. A 2022 Cell review by Damania and colleagues describes Epstein-Barr virus as “a ubiquitous, oncogenic virus that is associated with a number of different human malignancies as well as autoimmune disorders.”
Epstein-Barr virus has already been tied convincingly to multiple sclerosis and several cancers, and now, lupus joins that list. The virus has a sophisticated life cycle with latent and active phases, which allows it to hide from immune surveillance. During latency, Epstein-Barr virus expresses a small set of proteins that can subtly reshape host cell behavior. One of these proteins, EBNA2, acts as a transcription factor and can flip human genes on or off. This capacity to rewire B cells is critical for understanding how Epstein-Barr virus and lupus intersect. This basically means the virus is not just sitting quietly; it can reprogram immune cells in ways that push them toward autoimmunity.
Decades Of Clues Connecting Epstein-Barr Virus And Lupus
Long before the new Stanford paper, epidemiologists suspected a connection between Epstein-Barr virus and lupus. Patients with systemic lupus erythematosus often indicate higher Epstein-Barr viral loads, unusual antibody patterns, and earlier infection. Reviews by James and colleagues revealed multiple lines of evidence, including antibody profiles and molecular mimicry, that differed sharply between lupus patients and healthy controls. Furthermore, more recent work has strengthened those observations. A 2025 review by Czyż and colleagues concluded that “growing evidence points to EBV as a potential co-factor in systemic lupus erythematosus.” Meanwhile, Buonavoglia and colleagues in Italy detected Epstein-Barr virus DNA in saliva more often among lupus patients, especially those with oral lesions, than among controls.
Their team described how “this study highlights a significant association between the presence of EBV and both SLE and SLE-related oral lesions.” Population studies also indicate extremely high Epstein-Barr seroprevalence among people with lupus, often approaching universal exposure. Yet Epstein-Barr virus infects nearly everyone, while only a small minority develops lupus. That particular gap has helped fuel the debate. Was Epstein-Barr virus a genuine causal driver or just a passenger exploiting an already damaged immune system? Until recently, researchers lacked tools to track individual infected B cells at single-cell resolution. The new Science Translational Medicine study addresses that technical barrier directly, which is why many scientists view it as a turning point.
Mechanisms: Molecular Mimicry, Reactivation, And Autoreactive B Cells
Beyond epidemiology, scientists have proposed several mechanisms linking the Epstein-Barr virus and lupus. One important idea is molecular mimicry, where viral proteins resemble human proteins closely enough to confuse the immune system. If immune cells attack the virus, they may also attack look-alike self-proteins, including nuclear components targeted in lupus. Research on Epstein-Barr nuclear antigen 1 has shown cross-reactivity with lupus autoantigens in some patients. A second theme involves viral reactivation. Draborg, Duus, and Houen reviewed the field in 2012 and wrote, “This paper reviews EBV immunobiology and how this is related to SLE pathogenesis by illustrating uncontrolled reactivation of EBV as a disease mechanism for SLE.”
Their review highlighted how episodes of reactivation could periodically stimulate autoreactive B cells, stacking small injuries over time. The 2021 analysis by Houen and colleagues in Frontiers in Immunology emphasized that chronic or recurrent Epstein-Barr infection of immune cells associates with several systemic autoimmune diseases, including lupus and Sjögren’s syndrome. Together, these mechanistic proposals describe plausible routes from infection to immune misfiring. Yet until now, the pieces lacked a direct demonstration that Epstein-Barr virus infects exactly the B cells that drive antinuclear antibody production in lupus. The new Stanford work plugs that gap. It shows infected autoreactive B cells behaving like professional instigators, not bystanders.
Genes, EBNA2, And The Intersection Of Infection With Risk DNA
Lupus runs in families, yet no single gene explains the disease. Genome-wide association studies have identified many risk loci, mostly in immune pathways, each adding a modest effect. The question has always been how these genetic signals translate into real immune events. Work from Harley and colleagues in 2018 provided an important bridge. Using large genomic datasets, they revealed that the Epstein-Barr viral protein EBNA2 binds at many autoimmune risk loci, including those associated with lupus. A follow-up analysis from the U.S. Department of Veterans Affairs highlighted that “they found that the protein, EBNA2, has associations with lupus, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and type 1 diabetes.”
Hong and colleagues then demonstrated that EBNA2 can “extensively rewire” chromatin at these risk regions, altering which human genes become active in infected cells. This means that infection does not act alone. Epstein-Barr virus seems to read inherited risk variants like a map, using EBNA2 to switch on particular inflammatory programs. People with certain genetic backgrounds, therefore, experience a stronger, misdirected response to the virus. The new Stanford study builds directly on that foundation. It shows EBNA2 binding near key transcription factors in autoreactive B cells, which helps explain how risk genes interact with infection in real time. Lupus causes now look less like a simple sum of genes plus environment, and more like a specific conversation between viral proteins and susceptible DNA.
Inside The New Study That Rewired The Lupus Debate
Younis and colleagues at Stanford University wanted to know which human B cells harbor Epstein-Barr virus in lupus, and what those cells actually do. To tackle this issue, their team developed a highly sensitive sequencing platform to identify viral genetic material at single-cell resolution. In the abstract, they note, “here, we developed an EBV-specific single-cell RNA-sequencing platform.” They then applied this tool to blood samples from patients with systemic lupus erythematosus and from healthy controls. The team combined single-cell RNA sequencing with chromatin accessibility and protein analysis, which allowed them to see both infection status and activation state in each B cell.
The result was a detailed atlas of Epstein-Barr–infected B cells in lupus. In healthy individuals, only a tiny fraction of B cells contained latent virus, consistent with decades of earlier work. In lupus patients, infected B cells were more numerous and carried distinct surface markers associated with highly activated memory cells. Crucially, many of those cells produced antinuclear antibodies, the hallmark of lupus, strongly suggesting they participate directly in the disease. By combining multiple omics layers, the study moved the field beyond association toward a causal pathway, something previous epidemiological studies could not fully provide.
What The New Findings Show About Epstein-Barr Virus And Lupus
Image Credit: Pexels
The most provocative claim from Younis and colleagues is that Epstein-Barr virus actively reprograms autoreactive B cells into potent antigen-presenting cells. Their abstract concludes that “our results provide a mechanistic basis for EBV being a driver of SLE.” In lupus patients, Epstein-Barr–infected B cells were predominantly a CD27-positive, CD21-low memory subset, enriched for inflammatory transcription factors such as ZEB2 and TBX21. These cells did not merely produce autoantibodies. They also presented nuclear antigens to T cells, turning a small viral foothold into a full immune uprising. When the team cloned antibodies from infected lupus B cells, those antibodies targeted classic nuclear antigens linked to lupus nephritis and other organ damage.
By contrast, antibodies derived from infected B cells in healthy controls did not show the same autoreactivity. The group also mapped EBNA2 binding to regulatory regions of key genes in these cells, supporting the idea that viral proteins directly reshape the host genome’s activity. Together, these results outline a coherent sequence. Epstein-Barr virus infects a small pool of nuclear antigen-reactive B cells, switches on inflammatory programs, and turns them into antigen-presenting hubs that recruit many uninfected autoreactive cells. In that sense, the virus acts less like a lone saboteur and more like a field commander within the lupus immune system.
How Strong Is The Evidence That Epstein-Barr Virus Helps Cause Lupus?
No single study can prove causation in complex human disease, yet the current evidence is striking. Mechanistic work from Stanford sits on top of strong epidemiologic and immunologic foundations. In 2025, Ranjan and colleagues published a meta-analysis pooling 28 studies that measured Epstein-Barr markers in thousands of lupus patients and controls. Summarizing that work, the Lupus Foundation of America reported that “this analysis shows that the EBV virus can play a significant role in triggering autoimmunity and the development of SLE.” Their analysis found higher rates of Epstein-Barr DNA and antibody positivity among people with lupus than among healthy participants, even though overall exposure in the general population was already high.
Reviews by Draborg, James, and others add complementary evidence from viral load, T cell responses, and antibody fine specificity. Now, Younis and colleagues show that the virus infects precisely those B cells that produce antinuclear antibodies and that it transforms them into antigen-presenting cells. Taken together, these lines of evidence meet several criteria used in modern causal inference for complex diseases. The association is strong, consistent across studies, biologically plausible, and now supported by cell-level mechanics. However, Epstein-Barr virus is not the only factor. Many individuals harbor the virus yet never develop lupus. Genes, hormones, and other environmental triggers still matter, especially for people carrying multiple risk variants.
Read More: Is a Common Virus Causing Multiple Sclerosis?
What This Means For Patients Now And In The Future
For people living with lupus, these findings may feel unsettling yet also validating. They suggest that lupus causes are not random misfortunes, but traceable events involving a common virus and specific immune pathways. At the same time, the research does not change day-to-day treatment choices immediately. Current therapies still focus on calming the immune system with drugs that reduce B-cell numbers, T-cell activation, or cytokine signaling. Where the work does shift things is in long-term strategy. If Epstein-Barr virus helps drive lupus, then vaccines or antiviral approaches targeted at Epstein-Barr virus could eventually become preventive tools for high-risk groups. Robinson’s team notes ongoing development of Epstein-Barr vaccines, and other groups are testing aggressive B-cell-depleting strategies that aim to remove infected cells entirely.
Patient advocacy groups also stress that infections already belong on the list of important environmental triggers. The Lupus Foundation of America states plainly under environmental causes, “infections – most likely an infection with the Epstein-Barr virus.” For now, the practical steps remain the same. People with lupus should work closely with rheumatology teams, keep vaccinations up to date where appropriate, and address infections promptly. The bigger change sits at the level of understanding. The new data suggest that Epstein-Barr virus is not just a background actor. For many patients, it may be a central player in how lupus begins and persists, sitting alongside genetics and hormones as a key component of lupus causes.
Disclaimer: This article was created with AI assistance and edited by a human for accuracy and clarity.
Read More: COVID’s Long Shadow: Signs the Virus May Still Affect You Years Later